SCHEMBL2158677

SCHEMBL2158677

Nc1ccc(-c2ncn[nH]2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.61
IDO1 P14902 5/20 0.50
KDM4E B2RXH2 3/20 0.44
CYP3A4 P08684 2/20 0.44
HTT P42858 1/20 0.44
NPBWR1 P48145 1/20 0.42
ALDH1A1 P00352 3/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
TP53 P04637 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
LMNA P02545 1/20 0.42
PIK3CD O00329 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CB P42338 1/20 0.40
PIK3CG P48736 1/20 0.40
PRKDC P78527 1/20 0.40
METAP2 P50579 1/20 0.39
MAPT P10636 2/20 0.39
GFER P55789 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17541741 0.78 IDO1 (0.47) ENPP2IDO1KDM4ENPBWR1NPC1
SCHEMBL1440897 0.78 IDO1 (0.53) ENPP2IDO1NPBWR1ALDH1A1NPC1
SCHEMBL970723 0.78 IDO1 (0.61) ENPP2IDO1KDM4ECYP3A4NPBWR1
SCHEMBL9234967 0.78 NISCH (0.48) ENPP2IDO1KDM4ENPBWR1ALDH1A1
SCHEMBL4233813 0.78 IDO1 (0.56) ENPP2IDO1NPBWR1ALDH1A1GAA
SCHEMBL23718811 0.78 IDO1 (0.50) ENPP2IDO1NPBWR1ALDH1A1NPC1
SCHEMBL10022370 0.78 IDO1 (0.47) ENPP2IDO1KDM4ECYP3A4NPBWR1
SCHEMBL5372567 0.78 ENPP2 (0.51) ENPP2IDO1
SCHEMBL2721372 0.77 IDO1 (0.60) ENPP2IDO1KDM4ENPBWR1ALDH1A1
SCHEMBL3080603 0.76 ENPP2 (1.00) ENPP2IDO1KDM4EALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354444-B2 Substituted pyrrolidine-2-carboxamides HOFFMANN-LA ROCHE INC. (US) 2013-01-15 US claimed
EP-2340021-B1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES HOFFMANN LA ROCHE (CH) 2012-11-07 EP claimed
CN-102159207-A Substituted pyrrolidine-2-carboxamides HOFFMANN LA ROCHE 2011-08-17 CN claimed
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides F. HOFFMANN-LA ROCHE AG (CH) 2010-06-17 US claimed
US-20100075948-A1 Substituted Pyrrolidine-2-Carboxamides DING QINGJIE 2010-03-25 US claimed
EP-3481819-B1 COMPOUNDS AND THEIR USE FOR REDUCING URIC ACID LEVELS ACQUIST LLC (US) 2022-06-01 EP disclosed
CN-109476642-B Compounds and their use for reducing uric acid levels 阿奎斯特有限责任公司 2022-01-25 CN disclosed
US-20210236495-A1 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC (US) 2021-08-05 US disclosed
US-11020397-B2 Compounds and their use for reducing uric acid levels ACQUIST LLC (US) 2021-06-01 US disclosed
US-20200268757-A1 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC (US) 2020-08-27 US disclosed
US-20200197393-A9 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC 2020-06-25 US disclosed
US-10688095-B2 Compounds and their use for reducing uric acid levels ACQUIST LLC (US) 2020-06-23 US disclosed
CN-102159207-A Substituted pyrrolidine-2-carboxamides HOFFMANN LA ROCHE 2011-08-17 CN disclosed
EP-2340021-A1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES F. Hoffmann-La Roche AG (CH) 2011-07-06 EP disclosed
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides F. HOFFMANN-LA ROCHE AG (CH) 2010-06-17 US disclosed
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides F. HOFFMANN-LA ROCHE AG (CH) 2010-06-17 US disclosed
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides F. HOFFMANN-LA ROCHE AG (CH) 2010-06-17 US disclosed
WO-2010031713-A1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2010-03-25 WO disclosed
WO-2010031713-A1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2010-03-25 WO disclosed
US-20100075948-A1 Substituted Pyrrolidine-2-Carboxamides DING QINGJIE 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10688095-B2 Compounds and their use for reducing uric acid levels XDH, OAT, UGT2B7 ENPP2 1431/4885IDO1 3006/4885KDM4E 3534/4885
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides ARG2, CCNY, PYCR1 ENPP2 3413/4885IDO1 1946/4885KDM4E 272/4885
US-20210236495-A1 Compounds and Their Use for Reducing Uric Acid Levels XDH, OAT, URB2 ENPP2 636/4885IDO1 1588/4885KDM4E 4491/4885
US-20200268757-A1 Compounds and Their Use for Reducing Uric Acid Levels XDH, OAT, URB2 ENPP2 636/4885IDO1 1588/4885KDM4E 4491/4885
US-11020397-B2 Compounds and their use for reducing uric acid levels XDH, OAT, UGT2B7 ENPP2 1431/4885IDO1 3006/4885KDM4E 3534/4885
US-20100075948-A1 Substituted Pyrrolidine-2-Carboxamides ARG2, CCNY, PYCR1 ENPP2 3413/4885IDO1 1946/4885KDM4E 272/4885
US-20200197393-A9 Compounds and Their Use for Reducing Uric Acid Levels XDH, OAT, URB2 ENPP2 636/4885IDO1 1588/4885KDM4E 4491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.